Photobiomodulation (low-level laser therapy) for temporomandibular disorders: clinical efficacy, methodological quality, and dosimetric reporting — an umbrella review of systematic reviews and meta-analyses

Background To synthesise, at the level of systematic reviews (SRs) and meta-analyses (MAs), the efficacy of photobiomodulation (PBM)/low-level laser therapy (LLLT) for temporomandibular disorders (TMD), and to appraise the corpus’s methodological quality (AMSTAR-2), primary-study overlap, and dosimetry reporting. Methods Umbrella review of SRs/MAs of PBM/LLLT for TMD (PROSPERO: CRD420261458816). Five databases (Epistemonikos, PubMed/MEDLINE, Lens.org, LILACS, SciELO) were searched from inception to 25 July 2026 without language restriction. Quality was appraised with AMSTAR-2, overlap via corrected covered area (CCA), and dosimetry against a checklist; synthesis was narrative, and certainty was rated with GRADE using the estimates reported by the source meta-analyses. Results Of 231 records, 136 were unique and 32 SRs/MAs met inclusion. Most pooled estimates favoured PBM for short-term pain and maximum mouth opening (MMO; e.g., pain SMD − 0.55, 95% CI − 0.82 to − 0.27, Hanna 2021; MMO MD + 2.78 mm, 1.12 to 4.44, Máximo 2022), but magnitude was highly heterogeneous (I² up to 99%) and metrics non-comparable. Of 30 appraisable, 21 were AMSTAR-2 “Critically Low”, 1 “High”; just 11/32 reported a registered protocol. Across 30 reviews with retrievable study lists, 180 primary trials underpinned the corpus (45% included in ≥ 2 reviews); overall overlap was slight (CCA 5.48%). Wavelength and schedule were reported by 94%, but power density/irradiance (41%) and energy/dose (44%) in fewer than half. Conclusions PBM/LLLT may reduce temporomandibular pain (low certainty, GRADE), but the evidence is very uncertain about the effect on short-term mouth opening (very low certainty), and harms were not assessed. The review-level evidence is numerous but shows only slight primary-study overlap, is mostly of critically low methodological quality, and is inconsistent in reporting delivered-dose parameters. Pre-registered trials that report complete dosimetry would allow future syntheses to estimate the effect and its dose dependence more reliably. Registration PROSPERO CRD420261458816.

Authors

Institutions

Publication Details

Journal
BMC Oral Health
Published
2026-11-18
DOI
https://doi.org/10.1186/s12903-026-10479-z
Primary Topic
Laser Applications in Dentistry and Medicine
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Photobiomodulation (low-level laser therapy) for temporomandibular disorders: clinical efficacy, methodological quality, and dosimetric reporting — an umbrella review of systematic reviews and meta-analyses

Kapil Hazarika, Kadambari Bharali, Nilutpal Deuri
3 links
BMC Oral Health
Laser Applications in Dentistry and Medicine
article

Photobiomodulation (low-level laser therapy) for temporomandibular disorders: clinical efficacy, methodological quality, and dosimetric reporting — an umbrella review of systematic reviews and meta-analyses

Kapil Hazarika, Kadambari Bharali, Nilutpal Deuri
article en

Abstract

Background To synthesise, at the level of systematic reviews (SRs) and meta-analyses (MAs), the efficacy of photobiomodulation (PBM)/low-level laser therapy (LLLT) for temporomandibular disorders (TMD), and to appraise the corpus’s methodological quality (AMSTAR-2), primary-study overlap, and dosimetry reporting. Methods Umbrella review of SRs/MAs of PBM/LLLT for TMD (PROSPERO: CRD420261458816). Five databases (Epistemonikos, PubMed/MEDLINE, Lens.org, LILACS, SciELO) were searched from inception to 25 July 2026 without language restriction. Quality was appraised with AMSTAR-2, overlap via corrected covered area (CCA), and dosimetry against a checklist; synthesis was narrative, and certainty was rated with GRADE using the estimates reported by the source meta-analyses. Results Of 231 records, 136 were unique and 32 SRs/MAs met inclusion. Most pooled estimates favoured PBM for short-term pain and maximum mouth opening (MMO; e.g., pain SMD − 0.55, 95% CI − 0.82 to − 0.27, Hanna 2021; MMO MD + 2.78 mm, 1.12 to 4.44, Máximo 2022), but magnitude was highly heterogeneous (I² up to 99%) and metrics non-comparable. Of 30 appraisable, 21 were AMSTAR-2 “Critically Low”, 1 “High”; just 11/32 reported a registered protocol. Across 30 reviews with retrievable study lists, 180 primary trials underpinned the corpus (45% included in ≥ 2 reviews); overall overlap was slight (CCA 5.48%). Wavelength and schedule were reported by 94%, but power density/irradiance (41%) and energy/dose (44%) in fewer than half. Conclusions PBM/LLLT may reduce temporomandibular pain (low certainty, GRADE), but the evidence is very uncertain about the effect on short-term mouth opening (very low certainty), and harms were not assessed. The review-level evidence is numerous but shows only slight primary-study overlap, is mostly of critically low methodological quality, and is inconsistent in reporting delivered-dose parameters. Pre-registered trials that report complete dosimetry would allow future syntheses to estimate the effect and its dose dependence more reliably. Registration PROSPERO CRD420261458816.

BMC Oral Health
Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital (IN)
Good health and well-being
Laser Applications in Dentistry and Medicine
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon